- •Foreword
- •Preface
- •Contents
- •1.1 Introduction
- •1.2 Method
- •1.2.1 Databases
- •1.2.2 Dates
- •1.2.3 Keywords
- •1.2.4 Criteria for Inclusion
- •1.2.5 Criteria for Exclusion
- •1.2.6 Selection of Papers
- •1.3 Results
- •1.3.1 Subspecialty
- •1.3.2 Type of Telemedicine
- •1.3.3 Study Design
- •1.3.4 Final Conclusions of Papers
- •1.4 Discussion
- •References
- •2.1 Introduction
- •2.2 The Need for Diabetic Retinopathy Screening Programs
- •2.4 Guidelines for Referring Patients
- •2.7 Program Models for Diabetic Retinopathy Screening
- •2.9 Program Personnel and Operations
- •2.9.1 Primary Care Providers
- •2.9.2 Photographers
- •2.9.3 Clinical Consultants
- •2.9.4 Administrators
- •2.9.5 A Note to CEOs, Operations Directors, and Clinic Managers
- •2.10 Policies and Procedures
- •2.10.1 Sample Protocol 1
- •2.10.1.1 Diabetic Retinopathy Screening Services
- •Policy
- •Background
- •Procedure
- •2.10.2 Sample Protocol 2
- •2.10.2.1 Pupil Dilation Before Diabetic Retinopathy Photography
- •Policy
- •Background
- •Procedure
- •2.10.3 Sample Protocol 3
- •2.10.3.1 Diabetic Retinopathy Photography Review
- •Policy
- •Background
- •Procedure
- •2.11 Technical Requirements
- •2.11.1 Connectivity
- •2.11.2 Resolution
- •2.11.3 Color
- •2.11.4 Stereopsis
- •2.11.5 Compression
- •2.11.6 Enhancement
- •2.11.7 Pupil Dilation
- •2.11.8 Early California Telemedicine Initiatives Diabetic Retinopathy Screening
- •2.11.9 The American Indian Diabetes Teleophthalmology Grant Program
- •2.11.10 Central Valley EyePACS Diabetic Retinopathy Screening Project
- •2.12.1 Diabetic Retinopathy
- •2.12.1.1 ADA Guidelines Terms
- •2.12.1.2 Vitrectomy
- •References
- •3: Stereopsis and Teleophthalmology
- •3.1 Introduction
- •3.2 History of Stereopsis and Stereopsis in Ophthalmology
- •3.3 Technology and Photography
- •3.3.3 Imaging Fields
- •3.3.4 Image Viewing Techniques
- •3.3.5 Image Compression
- •3.4 Stereoscopic Teleophthalmology Systems
- •3.4.1 University of Alberta
- •3.4.4 Joslin Vision Network
- •3.5 Conclusion
- •References
- •4.1 Introduction
- •4.2 Methods
- •4.2.1 Main Outcome Measures
- •4.3 Results
- •4.3.1 Retinal Video Recording Versus Retinal Still Photography
- •4.3.2 Video Compression Analysis
- •4.4 Discussion
- •References
- •5.1 Introduction
- •5.1.1 Automated, Remote Image Analysis of Retinal Diseases
- •5.1.2 Telehealth
- •5.2 Design Requirements
- •5.2.1 Telehealth Network Architecture
- •5.2.2 Work Flow
- •5.2.3 Performance Evaluation of the Network
- •5.3 Automated Image Analysis Overview
- •5.3.1 Quality Assessment Module
- •5.3.2 Vascular Tree Segmentation
- •5.3.3 Quality Evaluation
- •5.4 Anatomic Structure Segmentation
- •5.4.1 Optic Nerve Detection
- •5.4.2 Macula
- •5.4.3 Lesion Segmentation
- •5.4.4 Lesion Population Description
- •5.4.5 Image Query
- •5.5 Summary
- •References
- •6.1 Introduction
- •6.3 Optical Coherence Tomography to Detect Leakage
- •References
- •7.1 Introduction
- •7.2 Patients and Methods
- •7.2.1 Participants
- •7.2.2 Methods
- •7.2.3 Statistics
- •7.3 Results
- •7.3.1 Reliability of Image Evaluation
- •7.3.2 Prevalence of Glaucomatous Optic Nerve Atrophy
- •7.4 Discussion
- •7.5 Perspectives
- •References
- •8.1 Introduction
- •8.1.2 Homology Between Retinal and Systemic Microvasculature
- •8.1.3 Need for More Precise CVD Risk Prediction
- •8.2.1 Retinal Microvascular Signs
- •8.2.2 Retinal Vessel Biometry
- •8.2.3 Newer Retinal Imaging for Morphologic Features of Retinal Vasculature
- •8.3 Associations of Retinal Imaging and CVD Risk
- •8.3.1.1 Risk of Pre-clinical CVD
- •8.3.1.2 Risk of Stroke
- •8.3.1.3 Risk of Coronary Heart Disease
- •8.3.2.1 Risk of Hypertension
- •8.3.2.2 Risk of Stroke
- •8.3.2.3 Risk of Coronary Heart Disease
- •8.3.2.4 Risk of Peripheral Artery Disease
- •8.3.3 Newer Morphologic Features of Retinal Vasculature
- •8.4 Retinal Imaging and Its Potential as a Tool for CVD Risk Prediction
- •References
- •9.1 Alzheimer’s Disease
- •9.2 Treatments
- •9.3 Diagnosis
- •9.6 Conclusions
- •References
- •10.1 Introduction
- •10.1.1 Stroke
- •10.1.2 Heart Disease
- •10.1.3 Arteriovenous Ratio
- •10.2 Purpose
- •10.3 Method
- •10.3.1 Medical Approach
- •10.3.2 Technical Approach
- •10.3.3 Output of Medical Data
- •10.4 Patients
- •10.5 Results
- •10.5.1 Medical History
- •10.5.2 Telemedical Evaluation of Retinal Vessels
- •10.5.2.1 Prevalence of Retinal Microangiopathy
- •10.5.2.2 Arteriovenous Ratio
- •10.5.2.3 PROCAM-Index
- •10.6 Discussion and Perceptive
- •10.6.1 Estimation of “Stroke Risk” Estimated by the Stage of Retinal Microangiopathy
- •References
- •11.1 Introduction
- •11.2 System Requirements
- •11.3 Fundus Camera
- •11.4 Imaging Procedure
- •11.4.1 Reading Center Procedure
- •11.5 Detection of Macular Edema
- •11.6 Implementation
- •11.7 Unreadable Images
- •11.7.1 Impact on Overall Diabetic Retinopathy Assessment Rates
- •11.7.2 Compliance with Recommendations
- •11.7.3 Challenges
- •11.7.4 Summary
- •References
- •12.1 Screening
- •12.2 Background
- •12.3 Historical Perspective in England
- •12.4 Methodology
- •12.4.1 The Aim of the Programme
- •12.5 Systematic DR Screening
- •12.6 Cameras for Use in the English Screening Programme
- •12.7 Software for Use in the English Screening Programme
- •12.9 Implementation in England
- •12.11 Quality Assurance
- •12.12 The Development of External Quality Assurance in the English Screening Programme
- •12.13 Information Technology (IT) Developments for the English Screening Programme
- •12.14 Dataset Development
- •12.15 The Development of External Quality Assurance Test Set for the English Screening Programme
- •12.16 Failsafe
- •12.17 The Epidemic of Diabetes
- •References
- •13.1 Introduction
- •13.2 Burden of Diabetes and Diabetic Retinopathy in India
- •13.3 Diabetic Retinopathy Screening Models
- •13.4 Need for Telescreening
- •13.5 Guidelines for Telescreening
- •13.6 ATA Categories of DR Telescreening Validation
- •13.7 Yield of Diabetic Retinopathy in a Telescreening Model
- •13.8 How Are Images Transferred
- •13.10 How Many Fields Are Enough for Diabetic Retinopathy Screening
- •13.11 Is Mydriasis Needed While Using Nonmydriatic Camera?
- •13.12 Validation Studies on Telescreening
- •13.12.1 Accuracy of Telescreening
- •13.12.2 Patient Satisfaction in Telescreening
- •13.12.3 Cost Effectivity
- •13.12.4 Telescreening for Diabetic Retinopathy: Our Experience
- •13.13 Future of Diabetic Retinopathy Screening
- •References
- •14.1 Introduction
- •14.2 Methods
- •14.3 Discussion
- •14.4 Conclusion
- •References
- •15.1 Introduction
- •15.1.1 Description of the EADRSI
- •15.5 State Support of Screening in the Safety Net
- •15.7 Screening Economics for Providers
- •15.8 Patient Sensitivity to Fees
- •15.9 Conclusion
- •References
- •16.1 Introduction
- •16.2 Setting Up the New Screening Model
- •16.2.1 Phase 1: Training
- •16.2.2 Phase 2: Evaluation of Agreement
- •16.2.3 Phase 3: Implementation of the Screening Model
- •16.3 Technologic Requirements
- •16.3.1 Data Management
- •16.3.2 Data Models
- •16.3.2.1 Data Scheme for Patient-Related Information
- •16.3.2.2 Data Scheme for Images
- •Fundus Camera VISUCAM Pro NM
- •PACS Server
- •ClearCanvas DICOM Visualizer
- •16.4 Results
- •16.4.1 Phase 2: Agreement Evaluation
- •16.4.2 Phase 3: Implementation of the Screening Model
- •16.5 Discussion
- •16.5.1 Evaluation of the Screening Model
- •16.5.2 Prevalence of DR
- •16.5.3 Quality Evaluation
- •16.6 Conclusion
- •References
- •17.1.3 Examination and Treatment
- •17.1.4 Limitations of Current Care
- •17.2 Telemedicine and ROP
- •17.2.2 Accuracy and Reliability of Telemedicine for ROP Diagnosis
- •17.2.3 Operational ROP Telemedicine Systems
- •17.2.4 Potential Barriers
- •17.3 Closing Remarks
- •17.3.1 Future Directions
- •References
- •18.1 Introduction
- •18.2 Neonatal Stress and Pain
- •18.3 ROP Screening Technique
- •18.4 Effect of Different Examination Techniques on Stress
- •18.5 Future of Retinal Imaging in Babies
- •References
- •19.1 Introduction
- •19.2 History of the Program
- •19.3 Telehealth Technologies
- •19.4 Impact of the Program
- •Selected References
- •Preamble
- •Introduction
- •Background
- •The Diabetic Retinopathy Study (DRS)
- •Mission
- •Vision
- •Goals
- •Guiding Principles
- •Ethics
- •Clinical Validation
- •Category 1
- •Category 2
- •Category 3
- •Category 4
- •Communication
- •Medical Care Supervision
- •Patient Care Coordinator
- •Image Acquisition
- •Image Review and Evaluation
- •Information Systems
- •Interoperability
- •Image Acquisition
- •Compression
- •Data Communication and Transmission
- •Computer Display
- •Archiving and Retrieval
- •Security
- •Reliability and Redundancy
- •Documentation
- •Image Analysis
- •Legal Requirements
- •Facility Accreditation
- •Privileging and Credentialing
- •Stark Act and Self-referrals
- •State Medical Practice Acts/Licensure
- •Tort Liability
- •Duty
- •Standards of Care
- •Consent
- •Quality Control
- •Operations
- •Customer Support
- •Originating Site
- •Transmission
- •Distant Site
- •Financial Factors
- •Reimbursement
- •Grants
- •Federal Programs
- •Other Financial Factors
- •Equipment Cost
- •Summary
- •Abbreviations
- •Appendices
- •Appendix A: Interoperability
- •Appendix B: DICOM Metadata
- •Appendix C: Computer-Aided Detection
- •Appendix D: Health Insurance Portability and Accountability Act (HIPAA)
- •Appendix F: Quality Control
- •Appendix H: Customer Support
- •Level 1
- •Level 2
- •Level 3
- •Appendix I: Reimbursement
- •Medicare
- •Medicaid
- •Commercial Insurance Carrier Reimbursement
- •Other Financial Factors
- •Disease Prevention
- •Resource Utilization
- •American Telemedicine Association’s Telehealth Practice Recommendations for Diabetic Retinopathy
- •Conclusion
- •References
- •Contributors
- •Second Edition
- •First Edition
- •Index
Appendix |
205 |
|
|
the OfÞce for the Advancement of Telehealth [83, 84]. A comprehensive review of licensure is available at the American Telemedicine Association State Telemedicine Policy Center website [66].
Tort Liability
Telehealth providers should consult with their professional liability carrier to ensure coverage in both originating and distant sites. Telemedicine may reduce liability risks through improved access and quality of care. However, telemedicine can also complicate traditional tort liability. Issues include which entity or physician owes a duty to the patient, standards of care, jurisdiction, and choice of law [59]. Although telemedicine providers should consult an attorney familiar with telemedicine law, the fundamental aspects of tort law are fairly uniform across jurisdictions:
¥A physician has a duty to a patient to act within the accepted standards of care.
¥Standards of care were violated.
¥A patient suffered an injury due to the violation of standard of care.
Duty
A physicianÕs duty arises from the physicianpatient relationship [85]. Telemedicine alters the traditional context of this relationship, but a telemedicine encounter is sufÞcient to establish the relationship [86].
Standards of Care
The telemedicine community is in early stages of establishing standards. The American Medical Association believes medical specialty societies should develop and implement telemedicine Òpractice parameters,Ó deÞned as educational tools and patient management strategies, to assist physiciansÕ clinical decision-making [87]. Because telemedicine standards of care are not well established, questions could arise regarding
appropriateness of a telemedicine DR evaluation, whether appropriate technology was selected (e.g., Validation Categories 1, 2, 3, or 4), or whether the outcome was sufÞcient. An example of a controversial outcome is failure to diagnose nondiabetic retinopathy pathology evident in images (e.g., venous occlusion, choroidal neovascular membrane) or not evident in images (choroidal melanoma anterior to the equator, peripheral retinal tear).
Consent
Ocular telehealth is considered part of a treatment or procedure [88]. Patients have the right to autonomous, informed participation in healthcare decisions [89]. Informed consent is required for clinical treatments and procedures, including those delivered via telemedicine. When treatments or procedures delivered through ocular telehealth are considered low risk and within commonly accepted standards of practice, signature consent may not be required [81]. Ocular telehealth services for DR may satisfy these criteria. Patients should be informed that they have a choice of telehealth and non-telehealth ocular treatments or procedures. Practitioners should provide patients information about the ocular telehealth program they would reasonably want to know, including:
¥Whether the services is novel or experimental
¥Differences between care delivered using ocular telehealth and face to face
¥BeneÞts and risks of using ocular telehealth in the patientÕs situation
¥Description of what is to be done at the patientÕs site and the remote site
Quality Control
Regardless of an imageÕs origin, providers should ensure the quality of medical images meet speciÞed standards. Policies should be in place to assure patient care and safety [77, 90, 91], including addressing non-DR eye diseases and Þndings
